OC-0129: Nitroglycerin decreases the hypoxic fraction of non-small cell lung cancer lesions  by Reymen, B. et al.
S58                                                                                     ESTRO 35 2016 
 _____________________________________________________________________________________________________ 
It is well known that MR data contains detailed information 
with high tissue contrast and that PET imaging gives 
molecular/biochemical information with high molecular 
sensitivity but what is the added value? A major goal with 
treatment planning is to delineate the tumor volume, which 
can be done with both MR and PET, but since the both 
modalities show different characteristics of the tumor the 
volume might differ between them. Challenges from the 
imaging point of view will be discussed. The availability to 
PET/CT is much higher and the challenges with this method 
are fewer. Some comparison of the two hybrid modalities will 
be done. The majority of PET studies are done with the 
tracer fluorodexyglucose, FDG, but beyond FDG a large 
number of tracer are available, all giving information about 
different biochemical properties of the tumor. A few of these 
tracers will be presented and discussed. 
 
SP-0127  
MR-PET for radiation oncology: the sub-volume 
opportunities  
D. Thorwarth
1University Hospital Tübingen Eberhard Karls University 
Tübingen, Tübingen, Germany 
1 
 
Purpose: To investigate the value of combined PET/MR 
imaging for biologically individualized radiotherapy (RT) 
planning.  
 
Methods: Hybrid PET/MR imaging offers the possibility to 
combine molecular information from PET with high resolution 
anatomical MR imaging. Consequently, a combination of the 
two different imaging data sets seems promising for improved 
automatic target volume delineation (TVD). An automatic co-
segmentation algorithm has been developed in our institution 
which derives probabilities of tumor presence by combining 
PET and MR data. Finally, the PET/MR-based probability maps 
are segmented to generate RT target volumes. Automatically 
segmented target volumes were compared to manual 
delineations from three experienced radiation oncologists.  
Furthermore, combined PET/MR imaging allows to assess PET 
and functional MR data at the same time. In the context of a 
clinical study, diffusion weighted (DW) as well as dynamic 
contrast enhanced (DCE) MRI were acquired in addition to 
anatomical images as well as FMISO and FDG PET images. 
Pairwise correlations of the different functional parameters 
were calculated in order to analyze for redundancy or 
complementarity respectively.  
 
Results: Automatic co-segmentation of tumor volumes based 
on combined FDG PET/MR imaging in head and neck cancer 
revealed robust and reproducible contours. The comparison 
of automatic and manual target volumes showed good 
agreement in terms of volume overlap. Deviation of the 
automatic compared to the manual contours was in the same 
order of magnitude as inter-observer variation. Compared to 
PET-based TVD, additional information from high resolution 
MR data improves automatic segmentation.  
A pairwise correlation analysis of parameters derived from 
FMISO PET, FDG PET, DW- and DCE-MRI on a voxel-level did 
only show moderate to low correlation coefficients hinting at 
a complementarity of the different investigated imaging 
methods. However, large inter-patient variations in terms of 
pairwise parameter correlations were observed.  
 
Conclusion: Functional and molecular imaging with combined 
PET/MR has the potential to improve TVD. At the same time, 
PET/MR allows to assess different levels of biological 
information which may in the future be important to derive 
individualized measures of radiation sensitivity. As a 
consequence, PET/MR imaging opens new doors for 
personalized RT planning and delivery in the near future. 
 
SP-0128  
MR-PET for radiation oncology: the implementation issues  
T. Nyholm
1Uppsala University, Immunology- Genetics and Pathology, 
Uppsala, Sweden 
1 
 
Imaging is fundamentally important in modern radiotherapy. 
For several of the most common diagnoses both PET and MR 
provide important information in the clinical decision making 
at the radiotherapy department. The combination of PET and 
MR in integrated PET/MR scanners could be the most efficient 
imaging modality for these patients. PET/MR has however 
primarily been designed for diagnostics and adjustments are 
needed to enable effective use in radiotherapy. This includes 
for example the ability to image the patient in treatment 
position, the ability to account for immobilization devices in 
the attenuation correction, and the development of adequate 
quality assurance methods.  
 
Proffered Papers: Radiobiology 2: Interplay between 
cancer stem cells, hypoxia and the radiation response  
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Purpose or Objective: Nitroglycerin is a nitric oxide donor 
being investigated because of its potential to increase 
tumour oxygenation. In phase II trial NCT01210378 
nitroglycerin is added to radical radiotherapy in patients with 
NSCLC stage IB-IV. Using a dedicated hypoxia PET tracer 
([18F]HX4; ref: Dubois et al, Proc Natl Acad Sci USA.2011) we 
investigate the effect of nitroglycerin on tumour hypoxia. 
Here, we report the results of the first 14 patients that 
completed the hypoxia scanning program. 
 
Material and Methods: A baseline [18F]HX4 PET scan (4h p.i.) 
was performed to measure hypoxia in the primary tumour 
and nodes. At least 48 hours later, a second [18F]HX4 PET 
scan was taken after application of a nitroglycerin patch 
(Transiderm nitro 5 mg). Between the two scans, patients did 
not receive any treatment. The primary tumour and involved 
nodes were defined on the planning FDG-PET-CT scan and 
fused with the HX-4 scan for analysis. The tumour-to-blood 
ratio (TBR) of [18F]HX4 and the Hypoxic Fraction (HF; the 
fraction of the volume with a TBR >1.4) were calculated for 
all lesions. The Wilcoxon signed rank test was used to 
evaluate differences between scan time points. 
 
Results: In 14 patients, the median interval between the 
scans was 4.5 +/-2.1 days (range: 2-7days). Seven patients 
(50%) exhibited hypoxia (HX-4 TBR>1.4) in the primary 
tumour and 4 of 10 patients (40%) had nodal disease with an 
HX4 TBR>1.4 in the lymph nodes. In total 9/14 patients (64%) 
showed hypoxia at baseline in the primary tumour and/or the 
lymph nodes. The effect of nitroglycerin on HX-4 uptake in 
hypoxic lesions was as follows: in 8/11 volumes (72%) and in 
6/9 patients (66%) nitroglycerin administration resulted in a 
decrease of the TBR of HX-4. Also, the median HF decreased 
from 12.9% to 1.2% (p=0.029), corresponding to a decrease in 
the median hypoxic volume of 5.4 cc to 0.5 cc (p=0.033). In 
the 7 non-hypoxic tumours and 6 non-hypoxic nodal volumes 
present at baseline, nitroglycerin caused a decrease of the 
TBR of HX-4 in 5, an increase in 5 and no effect in 3 lesions. 
None of the non-hypoxic lesions became hypoxic (TBR >1.4) 
after administration of nitroglycerin. 
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Figure 1: Example of HX-4 uptake in lung tumour before and 
after nitroglycerin. 
 
Conclusion: Nitroglycerin causes a significant decrease in the 
hypoxic fraction and hypoxic volume of a majority of hypoxic 
non-small cell lung cancer tumours and metastatic lymph 
nodes. This promising result encourages further investigation 
of nitroglycerin as a sensitizing agent in a selected 
population. CT-based perfusion studies and lab experiments 
(data not shown) suggest this effect is mediated by an 
inhibition of mitochondrial respiration rather than a vascular 
effect. 
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Purpose or Objective: Previous in vivo experiments 
demonstrated that hypoxia and perfusion determined during 
fractionated RT are associated with local tumour control (LC) 
in human head and neck squamous cell carcinoma (hHNSCC). 
In a randomized clinical trial Nimorazole improved LC and 
survival of patients with HNSCC treated with RT. Biomarker 
studies using tumour material from this trial indicate that 
hypoxic tumours predominantly benefit from nimorazole, 
supporting a predictive value for hypoxia assessment. 
However, this has not been prospectively evaluated for 
radiochemotherapy (RCTx) which represents the current 
standard of care in locally advanced head and neck cancer. 
The hypothesis of the ongoing study is that the 
microenvironmental parameters are also predictive for 
response to hypoxic cell sensitizing with nimorazole in 
combination with RCTx. 
 
Material and Methods: We studied 8 different human HPV-
negative and -positive HNSCC in a nude mice xenograft 
model. Irradiation was performed with 30 fractions (fx) in six 
weeks combined with weekly cisplatin (3 mg/kg i. p.). 
Nimorazole (0.3 mg/g i. p.) was applied before each 
irradiation and was started with the first fx or after 10 fx. 
Effect of nimorazole was quantified as LC 120/180 days after 
irradiation. For histological evaluation tumours were excised 
unirradiated or after 10 fx with and without nimorazole. 
Using quantitative image analysis, microenvironmental 
parameter such pimonidazole hypoxic volume (pHV), relative 
vascular area (RVA) and perfused fraction of vessels (PF) 
were determined. 
 
Results: The data of the cell lines show pronounced 
heterogeneity in the effect of nimorazole on local tumour 
control after fractionated radiochemotherapy. Nimorazole 
significantly improved local tumour control in four of the 
eight tumours. In the two responder models FaDu and SAS, 
nimorazole was equally effective when given from start of 
radiochemotherapy or after 10 fx. The treatment with both, 
RCTx and the application of nimorazole and cisplatin were 
well tolerated by the animals. Furthermore, pHV was 
significantly reduced after 10 fx RCT with and without 
nimorazole in all four responder models in contrast to the 
non-responders.  
 
Conclusion: Apparently, the decrease of pHV after the first 
fractions of RCTx has potential as a predictive biomarker for 
LC for combination of RCTx with nimorazole and should 
therefore be further evaluated in experimental FMISO 
analysis and also in clinical trials using hypoxic cell 
radiosensitisation during RCTx.  
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Purpose or Objective: There is increasing interest in defining 
a functional association between miRNAs, endogenous small 
non-coding RNA molecules that negatively regulate gene 
expression, and tumor radiation response, with the aim of 
rationally designing miRNA-based strategies to increase 
patient radiosensitivity. In this study, we investigated for the 
first time the ability of miR-875-5p, a miRNA the role of 
which in human cancer has not been so far investigated, to 
enhance the radiation response of prostate cancer (PCa) 
cells. 
 
Material and Methods: The search for miR-875-5p targets 
relevant to radiation response was carried out by prediction 
algorithms and confirmed by the luciferase assay. miR-875-5p 
reconstitution by miRNA mimics in PCa cell lines (DU145 and 
PC-3) was used to elucidate its biological role. Radiation 
response in miRNA-reconstituted and control cells was 
assessed by clonogenic assay, immunofluorescence-based 
detection of nuclear γ-H2AX foci and single-cell 
electrophoresis comet assay.  
 
Results: EGFR was predicted by 6 different algorithms and 
confirmed by luciferase assay as a direct target of miR-875-
5p. Given the role of EGFR in determining tumor cell 
resistance to ionizing radiation by promoting epithelial-to-
mesenchymal transition (EMT) and enhancing DNA-dependent 
protein kinase activity and DNA damage repair, we assessed 
whether miR-875-5p reconstitution in PCa cells was able to 
counteract EGFR-mediated radio-resistance. Indeed, miRNA 
ectopic expression significantly increased the sensitivity of 
both DU145 and PC-3 cell lines to radiation, as indicated by 
the reduced clonogenic cell survival. Consistently, the 
kinetics of accumulation and repair of γ-H2AX nuclear foci 
showed that the resolution of foci was significantly slower in 
miR-875-5p reconstituted cells compared to control cells. In 
addition, when a more direct assessment of radiation-induced 
DNA damage and repair at the single cell level was performed 
by the comet assay, DNA comet tail moments were found to 
be significantly extended in miR-875-5p reconstituted cells 
compared to control cells, confirming the ability of the 
miRNA to impair DNA repair processes. Ectopic expression of 
miR-875-5p in PCa cells was also able to counteract EMT as 
indicated by changes in cell morphology, marked 
cytoskeleton architecture rearrangements, reduced migration 
ability and increased mRNA and protein levels of E-cadherin 
and β-catenin, the two most important molecular players in 
the EMT process. 
 
Conclusion: Overall, results from this study support the 
clinical interest in developing a novel therapeutic approach 
for PCa based on miR-875-5p reconstitution to increase 
response to radiotherapy.  
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Purpose or Objective: Dual inhibitors of PI3K and mTOR do 
not efficiently radiosensitize glioblastoma multiforme stem 
cells (GBM-SCs). However, p53-proficient GBM-SCs are more 
